Delving into the Latest Updates on RecoRNA(Guangzhou) Biotechnology Co., Ltd. with Synapse

Overview

Tags

Other Diseases

Nervous System Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

RNA editing

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1
RNA editing	1

Top 5 Target	Count

Nav1.1(Sodium channel protein type I alpha subunit)	1

This is an open-label, single-center study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of intrathecal RC001 in patients with Dravet syndrome aged 2 to 18 years. The study includes a dose-escalation part followed by a fixed dose treatment part, with participant progression based on investigator-assessed safety and efficacy.

Start Date22 Dec 2025

Sponsor / Collaborator

Second Affiliated Hospital of Guangzhou Medical University

[+1]

100 Clinical Results associated with RecoRNA(Guangzhou) Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with RecoRNA(Guangzhou) Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with RecoRNA(Guangzhou) Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with RecoRNA(Guangzhou) Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Sep 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Preclinical

Login to view more data